Diagnosis of Parkinson’s Disease
A comprehensive overview of the clinical diagnostic criteria, examination findings, confirmatory biomarkers, and differential diagnosis challenges in Parkinson’s disease, based on current Movement Disorder Society guidelines.
5.1 Clinical Diagnosis: The MDS Criteria (2015)
PD remains a clinical diagnosis — there is currently no single definitive biomarker or laboratory test that confirms the diagnosis in a living patient with 100% certainty. The Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson’s Disease, published in 2015 by Postuma and colleagues (Movement Disorders), provide the current gold standard framework for diagnosis.
Diagnosis requires the presence of parkinsonism (bradykinesia plus at least one of: rest tremor or rigidity) as the core criterion. PD is then classified as:
- Clinically established PD: No absolute exclusion criteria; at least two supportive criteria; no red flags, OR one red flag balanced by one supportive criterion
- Clinically probable PD: No absolute exclusion criteria; supportive criteria may be balanced by red flags
Supportive Criteria (increase diagnostic confidence):
- Clear, dramatic beneficial response to dopaminergic therapy
- Presence of levodopa-induced dyskinesia
- Rest tremor of a limb on clinical examination
- Positive olfactory loss test or cardiac sympathetic denervation on MIBG scintigraphy
Absolute Exclusion Criteria (rule out PD):
- Unequivocal cerebellar abnormalities
- Downward vertical supranuclear gaze palsy (suggests PSP)
- Diagnosis of probable behavioral variant frontotemporal dementia or primary progressive aphasia within the first 5 years
- Parkinsonian features restricted to lower limbs for more than 3 years
- Treatment with a dopamine receptor blocker or dopamine-depleting agent in a dose and time course consistent with drug-induced parkinsonism
- Absence of observable response to high-dose levodopa despite at least moderate severity
- Unequivocal cortical sensory loss, clear limb ideomotor apraxia (suggests CBD)
- Normal functional neuroimaging of the presynaptic dopaminergic system
- Documentation of an alternative condition known to produce parkinsonism
Red Flags (raise suspicion of alternative diagnosis):
- Rapid progression to wheelchair within 5 years
- No progression of motor symptoms over 5+ years
- Early bulbar dysfunction (severe dysarthria or dysphagia within first 5 years)
- Inspiratory respiratory dysfunction
- Severe autonomic failure in the first 5 years
- Recurrent (>1/year) falls due to impaired balance within first 3 years
- Disproportionate anterocollis or contractures of hand or feet within the first 10 years
- Absence of any common non-motor features of PD despite ≥5 years of disease
- Unexplained pyramidal tract signs
- Bilateral symmetric parkinsonism throughout the course
5.2 Neurological Examination
The clinical examination of a patient with suspected PD includes:
- UPDRS/MDS-UPDRS: The Unified Parkinson’s Disease Rating Scale (and its MDS-revised version) is the standard quantitative assessment tool, covering motor and non-motor domains across 4 parts: non-motor experiences of daily living, motor experiences of daily living, motor examination, and motor complications.
- Hoehn & Yahr staging: A simplified 5-stage scale (I = unilateral; II = bilateral without balance impairment; III = mild postural instability; IV = severe disability but able to walk; V = wheelchair-bound)
- Tremor assessment: Distinguishing rest from postural/action tremor; examining for re-emergent tremor
- Gait analysis: Step length, cadence, arm swing, festination, turning strategy
- Pull test: Assessing postural reflexes
- Eye movement examination: Saccades (slowing suggests PSP), vergence, smooth pursuit
- Cognitive screening: MoCA (Montreal Cognitive Assessment); Frontal Assessment Battery
5.3 Diagnostic Investigations
| Investigation | Purpose | Sensitivity/Specificity for PD | Availability |
|---|---|---|---|
| DaTscan (DAT-SPECT) | Dopamine transporter imaging; confirms presynaptic dopaminergic deficit; distinguishes DaT-positive (PD, MSA, PSP, CBD) from DaT-negative (essential tremor, drug-induced) parkinsonism | Sensitivity 78–90%; Specificity 80–90% vs. ET | Widely available; FDA/EMA approved |
| MIBG cardiac scintigraphy | Sympathetic cardiac denervation; positive in PD, negative in MSA; distinguishes PD from MSA | Sensitivity ~80%; Specificity ~90% vs. MSA | Specialized centers |
| MRI brain | Excludes structural causes (tumor, hydrocephalus, multi-infarct state); specialized sequences show nigrosome-1 loss (“swallow-tail sign”) in PD; detects MSA/PSP-specific patterns | Conventional MRI: low sensitivity; Neuromelanin MRI and iron-sensitive sequences: improving | Widely available |
| Alpha-synuclein seed amplification assay (αSyn-SAA) | CSF or skin biopsy detection of misfolded alpha-synuclein via RT-QuIC or PMCA; highly sensitive and specific for synucleinopathies | CSF: Sensitivity ~88%; Specificity ~96% (Iranzo et al., 2021) | Research centers; becoming clinical |
| Skin punch biopsy (phospho-αSyn) | Detection of phosphorylated alpha-synuclein in peripheral autonomic nerve fibers; minimally invasive | Sensitivity ~80–90%; high specificity | Specialized centers; expanding |
| PET imaging (FDG, tau, amyloid) | Metabolic pattern; differentiates PD from PSP/CBD/MSA; detects co-pathology | High for differential diagnosis | Specialized/research |
| Genetic testing | LRRK2, SNCA, GBA1, PRKN, PINK1 etc.; See Genetics chapter | Variable by mutation | Clinical and research labs |
| Polysomnography | Confirms REM sleep behavior disorder (RBD) as prodromal biomarker; guides sleep management | High for RBD diagnosis | Sleep centers |
5.4 The Levodopa Challenge Test
The acute levodopa challenge remains a clinically valuable diagnostic tool. Patients are given a single suprathreshold dose of levodopa (typically 200–250 mg with carbidopa, after a 12-hour medication fast). A ≥30% improvement in UPDRS-III motor score supports the diagnosis of PD and predicts long-term levodopa responsiveness. A poor response raises suspicion for atypical parkinsonism. The apomorphine challenge test (subcutaneous injection) is an alternative with similar predictive value (Merello et al., 1997, Journal of Neurology).
5.5 Prodromal & Early Detection
The MDS has developed Research Criteria for Prodromal PD (Berg et al., 2015, Movement Disorders) to identify individuals at high risk before motor symptoms emerge. Established prodromal markers include: idiopathic RBD (highest risk, ~80–90% conversion over 14 years), hyposmia, constipation, and depression. Positive neuroimaging (DaTscan) or genetic testing (e.g., LRRK2 or GBA1 carrier status) increases risk further. This framework enables enrollment in neuroprotection trials targeting the prodromal phase — arguably the most promising therapeutic window.
References: Berg et al. (2015) Mov Disord; Iranzo et al. (2021) Lancet Neurology; Postuma et al. (2015) Mov Disord; Merello et al. (1997) J Neurology.
Navigation: ← Causes & Risk Factors | Genetics →